← Eichor
Condition: Select Advanced Solid Tumors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Select Advanced Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Se
Phase 1 · 3 location(s) · Molecure S.A. · NCT05759923A Study of YL202 in Patients With Advanced Solid Tumors
Phase 2 · 1 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07202364Clinical Trial of PM54 in Advanced Solid Tumors Patients.
Phase 1 · 3 location(s) · PharmaMar · NCT05841563An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors
Phase 1 · 7 location(s) · FBD Biologics Limited · NCT06487624A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 9 location(s) · Apollo Therapeutics Ltd · NCT06399757A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants Wit
Phase 1 · 48 location(s) · BeOne Medicines · NCT06427941First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Phase 1/Phase 2 · 8 location(s) · Egle Therapeutics · NCT06622486A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 13 location(s) · BeOne Medicines · NCT06803680Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589517A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Phase 1 · 9 location(s) · Avacta Life Sciences Ltd · NCT04969835A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
Phase 1 · 14 location(s) · DualityBio Inc. · NCT07141706A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612189Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tu
Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT05327010Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Phase 2 · 90 location(s) · Boehringer Ingelheim · NCT06581432A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Select
Phase 1 · 2 location(s) · Kupando GmbH · NCT07600476A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or
Phase 1/Phase 2 · 1 location(s) · AP Biosciences Inc. · NCT05473156A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06598371Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523529A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 · 8 location(s) · ALX Oncology Inc. · NCT07085091A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Phase 1/Phase 2 · 41 location(s) · Alentis Therapeutics AG · NCT06747585TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Portage Biotech · NCT04969315Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (
EARLY_Phase 1 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT05141474A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612176GTB-5550 in Advanced Solid Tumors
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07541573Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · Genmab · NCT07387068A Study of LY4175408 in Participants With Advanced Cancer
Phase 1 · 27 location(s) · Eli Lilly and Company · NCT07046923A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Phase 1 · 23 location(s) · Eli Lilly and Company · NCT06400472First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors
Phase 1 · 18 location(s) · CDR-Life AG · NCT06402201ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Phase 1 · 12 location(s) · Adcendo ApS · NCT06597721
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.